Haploid allogeneic NK cell therapy (Shanghai iCELL Biotechnology)

N/A

Report date: 2024/11/20 20:00:31

Base Information

Drug NameHaploid allogeneic NK cell therapy (Shanghai iCELL Biotechnology)
Drug Alias NameHaploid Donor-derived in Vitro Activated Natural Killer Cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionCell replacements
TargetsNot applicable
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesShanghai Icell Biotechnology Co., Ltd, Shanghai, China
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShanghai Icell Biotechnology Co., Ltd, Shanghai, China
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A